The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | The emerging role of ADCs and BiTES in small cell lung cancer
Francesco Grossi, MD, University of Insubria, Varese, Italy, gives an overview the recent developments in immunotherapies for small cell lung cancer (SCLC). Antibody-drug conjugates (ADCs), such as sacituzumab govitecan and rovalpituzumab tesirine, are awaiting trial results for potential use in practice. In contrast, tarlatamab, a bispecific T-cell engager (BiTE) approved in the US as a second-line treatment for SCLC, is a promising novel treatment option for patients. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
What is the case for the small cell lung cancer? We have some, I mean in small cell lung cancer it’s very difficult to have news because unfortunately for many years we haven’t had news. Now with immunotherapy it’s the real news. We have some ADCs in development, in particular we have sacituzumab govitecan and rovalpituzumab tesirine and others. We are waiting for the results of the trials because at the moment we don’t have a recommendation to use these agents in practice...
What is the case for the small cell lung cancer? We have some, I mean in small cell lung cancer it’s very difficult to have news because unfortunately for many years we haven’t had news. Now with immunotherapy it’s the real news. We have some ADCs in development, in particular we have sacituzumab govitecan and rovalpituzumab tesirine and others. We are waiting for the results of the trials because at the moment we don’t have a recommendation to use these agents in practice. The BiTE is a completely different story because tarlatamab is now approved in the US. It’s new because we obtained good results as a second-line treatment. So probably also in small cell lung cancer we have something new compared to the past.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
